Slide 1: Phase 2 Trial of Mecbotamab Vedotin (BA3011) in Non-Squamous NSCLC
Exhibit 99.1 Phase 2 Trial of Mecbotamab Vedotin (BA3011), CAB-AXL-ADC, Alone or in Combination with Nivolumab in Patients with Non- Squamous NSCLC BA3011 AXL NSCLC December 4, 2023 BioAtla | Overview 1 confidential
Slide 2: Important Notices & Disclaimers
Important Notices & Disclaimers This presentation (the “Presentation”) by BioAtla, Inc. (“we”, “us”, “our”, “BioAtla”, or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial
Slide 3: Phase 2 BA3011 Non-Squamous NSCLC Monotherapy Shows Encouraging Efficacy Signals
Phase 2 BA3011 Non-Squamous NSCLC Monotherapy 1.8 mg/kg Q2W shows encouraging efficacy signals Data Cut Date: 30Jun23 Prior PD-1/L1 treatment EGFR wild-type (N=15) Prior PD-1/L1 treatment (N=18) Best Overall Response, n (%) Confirmed PR 3 (20.0) 3 (16.7) Unconfirmed PR 2 (13.3) 2 (11.1) SD 7 (46.7)
Slide 4: BA3011-002 NSCLC interim analysis
BA3011-002 NSCLC interim analysis BA3011 Monotherapy 1.8 mg/kg Q2W confirmed BioAtla | Overview 14 Data Cut Date: 30Jun23
Slide 5: BA3011-002 NSCLC interim analysis
BA3011-002 NSCLC interim analysis BA3011 Monotherapy 1.8 mg/kg Q2W BioAtla | Overview 15 Data Cut Date: 30Jun23
Slide 6: Summary of Treatment Emergent Adverse Events (non-squamous NSCLC)
Summary of Treatment Emergent Adverse Events (non-squamous NSCLC) BA3011 BA3011 + Total monotherapy nivolumab (N=40) (n=23) (n=17) TEAEs with CTCAE grade 3 or 4 15 (65.2) 8 (47.1) 23 (57.5) Related grade 3 or 4 AEs 8 (34.8) 3 (17.6) 11 (27.5) Any serious TEAEs 9 (39.1) 5 (29.4) 14 (35.0) Related SAE
Slide 7: Treatment Emergent Adverse Events (Non-Squamous NSCLC)
Treatment Emergent Adverse Events (Non-Squamous NSCLC) * Any grade (≥15% of patients) OR grade ≥3 (≥3% of patients) in the study population Preferred term TEAEs of any grade, n (%) TEAEs of grade 3, n (%) Fatigue 14 (35.0) 1 (2.5) Diarrhea 10 (25.0) 1 (2.5) Constipation 9 (22.5) 0 Decreased appetite
Slide 8: BA3011 NSCLC Randomized Registrational Study Design
BA3011 NSCLC Randomized Registrational Study Design Two Potentially Registrational Paths Enabled via the FDA Type C Meeting nd 2 Line + • Open-label; control: docetaxel • Patients with NSCLC who have been previously treated with at least one prior line of therapy for metastatic disease • Dual primar